Published in Am J Respir Crit Care Med on August 08, 2008
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation (2012) 1.94
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther (2009) 1.66
Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov (2015) 1.18
Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest (2011) 1.13
Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. Br J Pharmacol (2011) 0.95
A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol (2012) 0.91
New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol (2011) 0.87
C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr Pharm Des (2010) 0.85
A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension. J Biol Chem (2013) 0.84
Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. Circulation (2014) 0.80
Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment. Anat Cell Biol (2016) 0.76
Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis. Br J Pharmacol (2014) 0.75
Natriuretic peptide receptors and heart failure: to B or not to B blocked? Naunyn Schmiedebergs Arch Pharmacol (2013) 0.75
Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice. Basic Res Cardiol (2016) 0.75
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther (1981) 6.71
Pulmonary arterial hypertension. N Engl J Med (2004) 6.69
Endothelial dysfunction in pulmonary hypertension. Circulation (2004) 2.82
Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res (2006) 2.59
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J (2006) 2.34
Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation (2001) 2.21
Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation (2001) 2.15
Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation (2006) 1.96
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
Effects of sildenafil citrate on human hemodynamics. Am J Cardiol (1999) 1.86
Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation (2007) 1.61
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology (2004) 1.57
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Localization of adenylyl cyclase isoforms and G protein-coupled receptors in vascular smooth muscle cells: expression in caveolin-rich and noncaveolin domains. Mol Pharmacol (2002) 1.42
High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem (1991) 1.40
Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett (1988) 1.27
Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol (2006) 1.27
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol (2005) 1.24
Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol (2002) 1.20
Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J (2004) 1.13
C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther (2005) 1.07
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol (2004) 1.06
NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation (1999) 1.02
Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol (2003) 1.02
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation (2003) 1.00
sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2001) 0.95
Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP. J Appl Physiol (1985) (1993) 0.94
Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 0.91
Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol (2000) 0.91
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol (2001) 0.90
M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol (1993) 0.90
Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis (1991) 0.89
Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest (2006) 0.88
Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest (1990) 0.87
Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med (Maywood) (2004) 0.85
Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens (1996) 0.81
Atrial natriuretic peptide in hypoxia. Peptides (2005) 0.80
Neutral endopeptidase inhibitors and the pulmonary circulation. Gen Pharmacol (1996) 0.80
Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs. Circ J (2007) 0.77
Reversal of pulmonary vascular remodelling following hypoxic exposure: no effect of infusion of atrial natriuretic factor and neutral endopeptidase inhibitor. Cardiovasc Res (1994) 0.76
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet (2005) 6.59
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension (2008) 3.99
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet (2007) 3.93
Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science (2007) 3.29
Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med (2007) 3.28
MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells (2010) 3.16
Rising out-of-pocket spending for chronic conditions: a ten-year trend. Health Aff (Millwood) (2009) 2.98
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension (2010) 2.82
The Rat Genome Database (RGD): developments towards a phenome database. Nucleic Acids Res (2005) 2.77
Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation (2007) 2.75
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation (2005) 2.35
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase. Circ Res (2008) 2.05
Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation (2012) 1.94
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab (2010) 1.85
NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol (2009) 1.81
Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. J Am Coll Cardiol (2005) 1.79
Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. Clin Sci (Lond) (2002) 1.78
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Small-molecule mimics of an alpha-helix for efficient transport of proteins into cells. Nat Methods (2007) 1.61
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Postconditioning protects against human endothelial ischaemia-reperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore. Eur Heart J (2011) 1.56
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med (2005) 1.56
Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci U S A (2003) 1.56
The F-box protein AhSLF-S2 physically interacts with S-RNases that may be inhibited by the ubiquitin/26S proteasome pathway of protein degradation during compatible pollination in Antirrhinum. Plant Cell (2004) 1.54
Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNgamma-dependent iNOS expression in the vasculature of healthy mice. Blood (2008) 1.53
Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol (2003) 1.51
Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem (2003) 1.49
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48
The F-box protein AhSLF-S2 controls the pollen function of S-RNase-based self-incompatibility. Plant Cell (2004) 1.47
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond) (2002) 1.46
Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem (2008) 1.41
The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther (2006) 1.41
Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation (2008) 1.39
Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived no in vivo. J Biol Chem (2005) 1.38
Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation (2005) 1.33
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A (2004) 1.26
Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res (2004) 1.25
Ordered mesoporous silica with large cage-like pores: structural identification and pore connectivity design by controlling the synthesis temperature and time. J Am Chem Soc (2003) 1.22
BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol (2003) 1.20
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem (2008) 1.19
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat (2011) 1.18
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation (2010) 1.16
A tri-continuous mesoporous material with a silica pore wall following a hexagonal minimal surface. Nat Chem (2009) 1.16
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11
Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol (2004) 1.09
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart (2011) 1.09
Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res (2007) 1.08
Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res (2013) 1.08
C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther (2005) 1.07
Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension (2013) 1.07
Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation (2006) 1.06
Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation (2002) 1.06
Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation (2010) 1.06
The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols. J Biol Chem (2009) 1.05
Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther (2005) 1.04
C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci U S A (2005) 1.04
AhSSK1, a novel SKP1-like protein that interacts with the S-locus F-box protein SLF. Plant J (2006) 1.04
Tools and strategies for physiological genomics: the Rat Genome Database. Physiol Genomics (2005) 1.04
Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol (2003) 1.02
Genome-wide SNP discovery from transcriptome of four common carp strains. PLoS One (2012) 1.02
Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis (2012) 1.02
Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor. J Endocrinol (2008) 1.01
BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAH. Hum Mol Genet (2012) 1.01
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.01
A consensus linkage map provides insights on genome character and evolution in common carp (Cyprinus carpio L.). Mar Biotechnol (NY) (2012) 1.00
cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 1.00
Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. Respir Res (2009) 1.00
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation (2003) 1.00
(6R)-5,6,7,8-tetrahydro-L-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm. Arterioscler Thromb Vasc Biol (2007) 0.99
Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J (2012) 0.98
Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol Biol Cell (2008) 0.98
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 0.97
Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther (2008) 0.97
Cobalt phosphate-modified barium-doped tantalum nitride nanorod photoanode with 1.5% solar energy conversion efficiency. Nat Commun (2013) 0.97
Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. J Biol Chem (2004) 0.96
Comparison of various niches for endothelial progenitor cell therapy on ischemic myocardial repair: coexistence of host collateralization and Akt-mediated angiogenesis produces a superior microenvironment. Arterioscler Thromb Vasc Biol (2012) 0.96
LXRα regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res (2011) 0.96
C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res (2013) 0.95
Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. Br J Pharmacol (2011) 0.95